Archives

The development of diverse treatment approaches for Leber congenital amaurosis (LCA) is necessary because no single modality will work for everyone affected. While development of gene [...]

Gene therapy is unequivocally the most advanced approach for treating retinal diseases like Leber congenital amaurosis (LCA). Of course, there’s LUXTURNA® which is FDA-approved and has restored [...]

The second panel session of the 2025 LCA Family Conference, “Participating in a Clinical Trial,” examined clinical trial development and participation from the researcher and patient [...]

Ledyard, Connecticut (6/4/2025)—Hope in Focus, a nonprofit dedicated to advancing treatments and cures for blindness caused by the rare inherited retinal disease Leber congenital amaurosis (LCA), [...]